What does the evidence say about Alpha Lipoic Acid Blood Glucose Meta-Analysis?

The current Migaku evidence database contains 2 reusable source documents for Alpha Lipoic Acid Blood Glucose Meta-Analysis. This answer focuses on benefits, uncertainty, and practical interpretation. - ALA reduced LPS-induced interleukin-1β (IL-1β) secretion in a concentration-dependent manner, whereas a modest but significant decrease in tumor necrosis factor-alpha (TNF-α) was observed only at the highest dose (2000 μM; p p p < 0.05). [Ko CY (2026); evidence level 4] - Type 2 diabetes mellitus (T2DM) is characterized by insulin resistance and chronic inflammation. [Ko CY (2026); evidence level 4] - This study investigated whether alpha-lipoic acid (ALA), a redox-active compound with established anti-inflammatory properties, can inhibit the activation of the nucleotide-binding oligomerization domain-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome in lipopolysaccharide (LPS)-stimulated Kupffer cells and mitigate inflammation-induced insulin resistance in FL83B hepatocytes. [Ko CY (2026); evidence level 4] - During the study period, 3 patients in the roflumilast group dropped out secondary to non-adherence (n=2) and the development of thyroid cancer (n=1), and 3 patients in the alpha-lipoic acid group also dropped out as a result of non-compliance. [Elsharab Asmaa (2025); evidence level 4] - Roflumilast treatment reduced FBG from 140 (17) to 118 (11) (P1<0.001), while alpha-lipoic acid reduced FBG from 139 (12) to 123 (10) (P1<0.001). [Elsharab Asmaa (2025); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.